[Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer]

Gan No Rinsho. 1985 May;31(5):487-93.
[Article in Japanese]

Abstract

A randomized controlled trial was made to compare the therapeutic result of oral high-dose medroxyprogesterone acetate (HD-MPA) versus mepitiostane (MS) in the treatment of postmenopausal breast cancer. MPA (1200 mg) was given p.o., b.i.d. to 47 patients and produced objective response in 19 of them (40.4%). Objective response was seen in 14 of the 40 control patients given MS p.o., b.i.d. (35.0%). Among patients with bone metastases, 6/19 (31.6%) for HD-MPA and 2/23 (15.4%) for MS showed objective response. The other merits of HD-MPA suggested in the study were improvement in performance status, anabolic effect and myeloprotective effect.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Androstanols / administration & dosage
  • Antineoplastic Agents / administration & dosage*
  • Breast Neoplasms / drug therapy*
  • Capsules
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Medroxyprogesterone / administration & dosage
  • Medroxyprogesterone / analogs & derivatives*
  • Medroxyprogesterone Acetate
  • Middle Aged

Substances

  • Androstanols
  • Antineoplastic Agents
  • Capsules
  • Medroxyprogesterone Acetate
  • Medroxyprogesterone
  • mepitiostane